HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Money

RA Capital banks $75M for a biotech SPAC

Research Alliance III follows a few months after Cormorant Asset Management priced a $150 million IPO for its own blank-check entity.

By BioPharma Dive · May 21, 2026 · via BioPharma Dive
RA Capital banks $75M for a biotech SPAC

Image: BioPharma Dive

This is an aggregated industry headline. Read the full story at BioPharma Dive →

Tags
moneyformat:headlineheadlineBioPharma Dive
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Money
All Money →
Alphabet's AI biotech Isomorphic Labs bags $2.1B series B to fuel next-gen drug design model
MoneyFierceBiotech ↗
Alphabet's AI biotech Isomorphic Labs bags $2.1B series B to fuel next-gen drug design model
If any proof was needed that big money is still available for AI drug development, look no further than the 10…
May 13, 2026
CSL slashes revenue projection and takes $5B impairment as interim CEO flags R&D misses, market erosion
MoneyFiercePharma ↗
CSL slashes revenue projection and takes $5B impairment as interim CEO flags R&D misses, market erosion
CSL has slashed its revenue projection for the fiscal year from $15.8 billion to $15.2 billion, in another ind…
May 12, 2026
Odyssey’s CEO sees $304M IPO as chance to create a ‘little large pharma’
MoneyFierceBiotech ↗
Odyssey’s CEO sees $304M IPO as chance to create a ‘little large pharma’
Odyssey Therapeutics has become the latest biotech to voyage to the public markets via an upsized $304 million…
May 11, 2026